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Prominent among molecules that control neovascular processes is vascular endothelial growth factor (VEGF). The VEGF
ligands comprise a family of well-studied mitogens/permeability factors that bind cell surface receptor tyrosine kinases.
Targets include VEGF receptor-1/Flt1 and VEGF receptor-2/Flk1. Mice lacking genes for VEGF ligand or VEGF receptor-2
die early in gestation, making it difficult to determine the precise nature of underlying endothelial cellular behavior(s). To
examine the effect(s) of VEGF signaling on cell behavior in detail, we conducted loss-of-function studies using avian
embryos. Injection of soluble VEGFR-1 results in malformed vascular networks and the absence of large vessels. In the most
severe cases embryos exhibited vascular atresia. Closely associated with the altered phenotype was a clear endothelial cell
response—a marked decrease in cell protrusive activity. Further, we demonstrate that VEGF gain of function strikingly
increased cell protrusive activity. Together, our data show that VEGF/VEGF receptor signaling regulates endothelial cell
protrusive activity, a key determinant of blood vessel morphogenesis. We propose that VEGF functions as an instructive
molecule during de novo blood vessel morphogenesis. © 2000 Academic Press
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VINTRODUCTION
The de novo assembly of blood vessels from mesoder-
mally derived cells is referred to as vasculogenesis. The
process requires both the recruitment of mesodermal cells
to the endothelial lineage and the organization of their
progeny into microvessels (Coffin and Poole, 1988; for
review see Drake et al., 1998; Drake and Little, 1998).
Vasculogenesis establishes a complex system of diversely
sized vessels arranged in a precise spatial pattern.
Vascular endothelial growth factor (VEGF) is required for
vasculogenesis. The VEGF family includes VEGF (Connolly
et al., 1989; Ferrara and Henzel, 1989) and its related ligands
VRF/VEGF-B (Olofsson et al., 1996), VEGF-C (Joukov et al.,
1996), VEGF-D (Yamada et al., 1997), and placental growth
factor (Maglione et al., 1991). The known receptors are
VEGFR-1/Flt-1 (DeVries et al., 1992; Shalaby et al., 1995,
1 In memory of Jill Eckman Hungerford, Ph.D.—student, friend,
and splendid colleague (August 19, 1965—December 12, 1999);phttp://www.jbpierce.com/Staff/Hungerford.html.
1781997), VEGFR-2/Flk-1 (Millauer et al., 1993; Terman et al.,
1992), and neurophilin (Soker et al., 1998).
Mouse embryos lacking a single VEGF allele exhibit
bnormal vascular development and do not survive beyond
1 days postcoitum (Carmeliet et al., 1996; Ferrara et al.,
996). This observation emphasizes the importance of
EGF levels to normal vascular morphogenesis. Early le-
hality and the fact that there are several VEGF-related
olecules and multiple receptors have made it difficult to
ssign morphogenic activity(ies) to VEGF/VEGF receptor(s)
ignaling.
Avian embryos are well suited to experimental treatment
nd direct observation. The experimental equivalent of a
onditional gene knockout can be accomplished in avian
mbryos and examined at precisely timed intervals. More-
ver, our studies in avians and recent work in mice strongly
uggest that molecular regulation of vasculogenesis is
ighly conserved (Drake et al., 1997; Drake and Fleming,
000).
To evaluate the consequences of inhibition or loss of
EGF function during vasculogenesis, microinjection ex-
eriments were conducted using soluble forms of the
0012-1606/00 $35.00
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179VEGF Regulates Cell BehaviorVEGFR-1. The rationale underlying these experiments is
that soluble receptor depletes the level of bioavailable
VEGF. Work by others has shown that soluble VEGFR-1
inhibits VEGF-dependent proliferation of endothelial cells
in culture (R&D Systems, Minneapolis, MN), suppresses
retinal neovascularization (Aiello et al., 1995), and causes a
neonatal lethal phenotype in mice (Gerber et al., 1999). In
our hands embryos injected with either the murine or the
human recombinant form of soluble VEGFR-1 gave the
same experimental result—vascular atresia of both small-
and large-caliber vessels and a loss of endothelial cell
protrusive activity. In the present study we define protru-
sive activity as the behavior that allows primordial endo-
thelial cells to form the extended spindle-shaped processes
required to establish patterned vascular polygons. Our, in
vivo, results are entirely consistent with VEGF and VEGF
receptor mouse knockout phenotypes (Carmeliet et al.,
1996; Ferrara et al., 1996; Fong et al., 1995; Shalaby et al.,
1995).
To examine the effects of overstimulating VEGF/VEGF
receptor signaling on endothelial cell protrusive activity,
experiments were conducted using recombinant human
VEGF165. Treated embryos showed a striking increase in
endothelial cell protrusive activity and exhibited vascular
hyperplasia. Based on this vigorous response to overstimu-
lation, we assume that normal vascular patterning requires
a carefully regulated degree of protrusive activity.
In summary, the data below show that VEGF/VEGF
receptor signaling can modulate endothelial cell extension
and protrusion activity. Embryos subjected to reduced lev-
els of VEGF signaling show sharply curtailed activity,
whereas embryos overstimulated with exogenous VEGF165
display excessive endothelial protrusions.
METHODS AND MATERIALS
Two forms of VEGFR-1 were used in this study. The first was a
truncated soluble receptor consisting of the first three extracellular
domains of murine Flt-1 fused to a murine Fc IgG-g2B (mFlt
FIG. 1. Microinjection of soluble VEGFR-1. Whole-mounted qua
VEGF or soluble VEGF receptor, then incubated for 7 h. (a) A normal
(single bolus, 10 fmol in a 10 nl volume). This treatment results i
lateral vessels. The most severe anomalies occur on the injected sid
VEGFR-1. The inhibition causes local failure of vasculogenesis. Co
Methods and Materials for details). Embryos are viewed en face, from
ndothelial cells. ec, endocardium; sv, sinuous venosus; da, dorsal
IG. 2. Increasing the amount of soluble VEGFR-1 increases the ex
y injecting both sides of the embryo results in vascular atresia (t
essels formed caudal to the anterior intestinal portal (arrows, a). In
hat successfully formed in the lateralmost regions were partially d
replaced” by a polygon-like vascular pattern (arrowheads, a). An i
ndothelial cells lack protrusions. Instead, the endothelial cells ar
pparent that the endothelial cell clusters failed to acquire a
mmunofluorescence (c). Original magnification 533, 1103, and 1743,
Copyright © 2000 by Academic Press. All right03-IgG). This construct was expressed in CHO cells and purified
y protein A–Sepharose (Ferrara et al., 1998). The truncated reagent
as the same binding affinity and in vitro neutralizing activity as
he full length Flt-IgG when injected systemically, but has a longer
alf-life.
The second version of soluble VEGFR-1 was purchased from
&D Systems (Minneapolis, MN). This reagent was generated by
using DNA sequence encoding soluble human Flt1 to the Fc region
f human IgG. The fusion protein was expressed in Sf21 cells using
baculovirus system. The cDNA encoded a truncated form of Flt1
acking the seventh IgG-like domain, the transmembrane domain,
nd the intracellular domain.
Two forms of rhVEGF165 were used. One was purchased from
&D Systems, the other was prepared at Genentech, Inc. Both
eagents yielded the same experimental result. All experimental
nd control reagents were microinjected as described previously
Drake et al., 1992).
Controls for the IgG Fc portion of the chimeric proteins con-
isted of microinjection of various mouse IgGs, including IgG1 and
gG2, and several irrelevant mouse monoclonal antibodies as
reviously reported (see Drake et al., 1995, for details). As a control
or recombinant VEGF165 similar molar concentrations (10 fM) of
ative human IgG were microinjected (Drake and Little, 1995). In
ll cases control-injected embryos received the same volumes, at
dentical positions and stages, as experimental specimens. All
egative control embryos exhibited normal vessel morphology as
udged by QH1 immunostaining.
The quail vascular endothelial cell marker monoclonal antibody,
H1, was obtained from the Developmental Studies Hybridoma
ank maintained by the University of Iowa (Iowa City, IA 52242).
he rabbit polyclonal antibody to chicken transcription factor
AL1 has been previously described (Drake et al., 1997). Secondary
uorochrome-conjugated antibodies were purchased from Jackson
mmunological Research Laboratories, Inc (West Grove, PA 19390).
Detailed methods for preparing, microinjecting, and immunola-
eling two- to nine-somite quail embryos have been described
reviously (Drake et al., 1992). In brief, staged embryos are re-
moved from the yolk by means of a paper ring and placed on an agar
bed. Using a transmitted light stereomicroscope, a micromanipu-
lator, and an injection pump, nanoliter-sized aliquots of reagent
(approximately 1 ng/nl in 10- or 20-nl aliquots) are delivered to the
splanchnic mesoderm at the site of aortic morphogenesis. Embryos
are incubated (39°C) for either 5 or 7 h (see Tables 1 and 2), fixed,
bryos (1- to 9-somite stage) were microinjected with recombinant
mite embryo. (b) The results of injecting a soluble form of VEGFR-1
ure to form an aorta (asterisk) and conspicuously underdeveloped
acket), where endogenous VEGF ligand was neutralized by soluble
injections exhibited no detectable anomalies (data not shown; see
ve, and immunostained with the QH1 antibody, a marker for quail
a; vn, vascular network. Original magnification 603; bar, 90 mm.
of vascular abnormalities. Doubling the amount of soluble receptor
oluses, 10 fmol each). At low magnification it is apparent that no
, the dorsal aortae are absent (double-headed arrow, a). The vessels
ped at the time of microinjection. Note that the sinus venosae are
ediate level of magnification suggests that QH1-immunoreactive
sent in widely separated clusters (b). At higher magnification it is
al, bipolar, shape and to extend protrusions, based on QH1il em
9-so
n fail
e (br
ntrol
abo
aort
tent
wo b
deed
evelo
nterm
e pre
normrespectively. Bars, 100, 48, and 30 mm.
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181VEGF Regulates Cell BehaviorFIG. 3. Soluble VEGF receptor-1-treated endothelial cells do not form protrusions. To confirm the absence of protrusions after soluble
VEGFR-1 treatment, endothelial cell clusters were examined at high optical resolution. Observation of clusters with both differential
interference optics (a) and QH1 immunofluorescence (b) failed to detect cellular protrusions. Thus, at the resolution limit of light
microscopy, treated endothelial cells are devoid of normal cellular protrusions; the cells exhibit a compact morphology instead of a normal
extended spindle-like shape. Original magnification 3003.
FIG. 4. Injection of VEGF induces a dramatic increase in protrusive activity. Compare the polygonal arrays in b with the equivalent region
in the stage-matched normal embryo, a. (b) A 2-somite embryo injected with 12.5 ng of human recombinant VEGF165, incubated for 7 h,
and then fixed. This treatment causes striking increases in endothelial cell protrusive and extension behavior. The aberrant cellular
processes obliterate the normal vascular pattern by invading areas that are typically avascular (asterisks). Original magnification 603.
Copyright © 2000 by Academic Press. All rights of reproduction in any form reserved.
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182 Drake et al.and prepared for immunofluorescence microscopy as described
previously.
Laser scanning confocal microscope images were acquired with a
Bio-Rad MRC1024 laser scanning confocal microscope exported to
Adobe PhotoShop image processing software and rendered as color
images. A 103 objective lens was used to acquire images of the
vasculogenic region of one- to nine-somite embryos. The images
are projections of 20 optical planes collapsed to form complete
representation of all endothelial cells in the optical field (Drake et
al., 1997). The viewer’s perspective is en face in all images. This
sampling represents approximately 100 mm along the dorsoventral
xis, a depth more than sufficient to sample the entire thickness of
he embryonic vasculature caudal to the midbrain and cranial of
he region of Hensen’s node. The differential interference contrast
DIC) images were acquired on a Leica DMR microscope using
1003 oil immersion lens and a Photometrics Quantix CCD
amera.
RESULTS
The blood vessels of a normal nine-somite quail embryo
immunolabeled with the endothelial marker QH1 are de-
picted in Fig. 1a. The image was acquired using a laser
scanning confocal microscope and represents the endpoint
of an assay designed to assess vascular pattern formation.
The primitive vasculature exhibits significant diversity; the
salient features are the proximal endocardial primordia, the
lateral polygonal networks, the paired medially positioned
dorsal aortae, and the sinus venosae. Each of these rudimen-
tary vascular elements is characterized by well-defined
boundaries surrounding clearly delineated avascular zones
TABLE 1
Embryos with One to Nine Somites Were Injected and Incubated
for 5 (n 5 5) or 7 h (n 5 120)
Soluble VEGFR-1-injected embryos
Somite Embryo count
Vascular
anomalies?
Yes No
1 3 = —
2 8 = —
3 23 = —
4 26 = —
5 26 = —
6 13 = —
7 14 = —
8 6 = —
9 2 = —
Total 125 125 0(dark areas).
Copyright © 2000 by Academic Press. All rightInhibition of Endogenous VEGF/VEGF Receptor
Signaling Disrupts Vasculogenesis
To elucidate the function(s) of VEGF/VEGFR-1 signaling,
loss-of-function experiments were conducted. Embryos
were injected with one of two preparations of soluble
recombinant VEGF receptor-1/IgG-Fc chimeric proteins.
Striking malformations were observed when one- to nine-
somite embryos received a single VEGFR-1 bolus (10 fmol
in a 10-nl volume; Table 1). Soluble VEGFR-1-treated em-
bryos failed to form vascular elements on the injected side
(Fig. 1b, asterisk). Vascular development on the uninjected
side, while not completely normal, appeared less perturbed;
for example, an aortic primordium is identifiable. Vascular
malformations on the injected side were severe from the
level of the cranialmost somite to the segmental plate
mesoderm (Fig. 1b, bracket). Within this aberrant field,
anomalies range from significant at the midline to moder-
ate in the more lateral vessels. In the most severely affected
area, the aortae is absent and endothelial cells are present in
scattered abnormal clusters (asterisk). Vessels outside the
bracketed area were also abnormal; for instance, cranial
extraembryonic vessels lateral to the forebrain were
disrupted (arrowhead). Every soluble VEGFR-1-treated em-
bryo exhibited marked vascular anomalies (n 5 125, see
Table 1).
To investigate the effects of higher doses of soluble
VEGFR-1 embryos were injected on both sides of the axis
(10 fmol per site; Fig. 2a). Compared to stage-matched
normal embryos (Fig. 1a), the morphogenesis of the dorsal
aortae was completely blocked. Additionally, embryos re-
ceiving a double dose had truncated endocardial primordia
and no recognizable sinus venosae (compare Fig. 1a with
2a). During normal morphogenesis a sinus venosus forms at
the most caudal aspect of each endocardial primordium.
Examination of the corresponding regions in double-
injected embryos revealed the presence of blood vessels
arranged in polygons, instead of sinus venosae (arrowheads).
Soluble VEGFR-1 also profoundly altered the morphogen-
esis of the polygonal primary vascular networks. Compared
to normal embryos (Fig. 1a), vasculogenesis was most
severely affected adjacent to the midline (Fig. 2b). Analysis
of vasculogenesis at progressively older embryonic stages
indicates that this region is the site where angioblasts and
endothelial polygons have most recently formed. At higher
magnification immunofluorescence shows primordial en-
dothelial cells present in tight clusters (Fig. 2c). Such cells
lack the protrusions characteristic of this stage of vascular
morphogenesis, as judged by QH1 immunofluorescence
(Figs. 2c, 3, 5c, and 6). The failure of treated endothelial
cells to engage in normal extension and protrusive activity
(Fig. 5a) was manifested by both the absence of vascu-
lar polygons and the failure to form larger vessels (Figs. 2
and 5c).
While QH1 immunostaining is an accepted marker of
quail endothelial cells it was possible that the apparent
absence of protrusions in treated embryos was due to a lack
s of reproduction in any form reserved.
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183VEGF Regulates Cell Behaviorof QH1 expression on cell processes. Embryos were exam-
ined using DIC optics to confirm that the introduction of
soluble VEGFR-1 directly affected protrusive activity and
not QH1 expression on cell processes. Figure 3b shows
three clusters of QH1-immunoreactive endothelial cells.
When these and similar clusters were examined using DIC
optics the protrusions, characteristic of normal primordial
endothelial cells, were absent (Fig. 3a).
VEGF Regulates Endothelial Protrusive Activity
To pursue the possibility that VEGF/VEGF receptor sig-
naling regulates endothelial cell protrusive activity, recom-
binant human VEGF165 was used to conduct stimulatory,
or gain-of-function, studies. Analysis of treated embryos
showed endothelial cell behavior that consistently violated
the normal constraints required for correct vascular pat-
terning. Compare normals in Fig. 4a to the treated speci-
mens in Fig. 4b. A conspicuous feature of this phenotype
was the presence of excessive and inappropriate endothelial
cell protrusions. For example, aortic endothelial cells ex-
tended cell processes both toward the midline and into
regions that are normal avascular (Fig. 4a, asterisks). The
abnormal protrusions resulted in the formation of blood
vessels that connected the aortic rudiments (cardiac out-
flow) directly to the sinus venosus (cardiac inflow) (Fig. 4b,
arrowhead). Excessive extension and protrusive activity
responses were observed in all VEGF-injected specimens
(see Table 2).
Can Loss-of-Function Effects Be Explained by
Diminished Numbers of Endothelial Cells?
VEGF is an endothelial cell mitogen; therefore, experi-
ments were conducted to evaluate whether the loss-of-
function phenotype was based on a gross decrease in the
TABLE 2
Embryos with Two to Eight Somites Were Injected and Incubated
for 5 (n 5 7) or 7 h (n 5 61)
Recombinant human-VEGF165-injected embryos
Somite
Embryo
count
Vascular
anomalies?
Yes No
2 6 = —
3 8 = —
4 13 = —
5 18 = —
6 18 = —
7 4 = —
8 1 = —
Total 68 68 0numbers of angioblasts and/or primordial endothelial cells. p
Copyright © 2000 by Academic Press. All rightithin the embryo proper, the relative proportions of
ngioblasts and endothelial cells can be evaluated using
ntibodies to TAL1/SCL (TAL1) and the QH1 marker.
uclear localization of the TAL1 transcription factor, in
he absence of cell surface QH1 staining, is characteristic of
ngioblasts; whereas, the presence of both markers identi-
es endothelial cells (for details see Drake et al., 1997; also
ee Drake and Fleming, 2000). For both cell types the
resence of nuclear TAL1 immunofluorescence allows as-
essment of the numbers of vasculogenic cells in a given
egion.
During the early stages of de novo blood vessel assembly,
ndothelial cells assume an extended, mostly bipolar shape
s judged by green QH1 immunofluorescence (Fig. 5a). Such
ells often have one protrusion anchored at the vertex of a
resumptive polygon and one process extending toward a
earby companion cell (Fig. 5a, arrow). The corresponding
ed nuclear fluorescence indicates the TAL1 transcription
actor. Comparing Fig. 5a with 5b demonstrates that as few
s two cells can complete the side of a vascular polygon
note the two red nuclei separated by the arrow). Thus,
orphogenesis of the polygonal pattern requires only a
mall number of founder cells. Despite more than adequate
ell numbers and close proximity (arrowhead, Figs. 5c and
d), no extended, bipolar cells are present in soluble
EGFR-1-treated embryos. The arrowheads indicate a posi-
ion where a vascular element might have formed under
ormal conditions (Figs. 5c and 5d). These data confirm that
he failure of vascular polygon formation is not due to
nsufficient endothelial cell numbers. Rather the data con-
titute direct evidence that during vasculogenesis VEGF
egulates a morphogenic activity required to produce a
ormal vascular pattern.
VEGF/VEGF Receptor Signaling and the
Appearance of the Endothelial Lineage
The data above demonstrate that there are significant
numbers of endothelial cells present in embryos injected
with soluble VEGFR-1 receptor. However, it was unclear
whether the vascular cell population, in treated embryos,
was derived directly from the mesoderm via vascular pre-
cursor cells, or by endothelial cell replication, or both.
Accordingly, embryos were injected at the one- to two-
somite stage, a period prior to the formation of overt blood
vessels or their primordia (see Table 1). Injection at such
early stages permitted evaluation of the effects of soluble-1
receptor on the genesis of the endothelial cell lineage.
Analysis of soluble VEGFR-1-treated embryos double-
immunolabeled with QH1 and TAL1 allowed vascular
precursor cell numbers to be monitored. Red fluorescence,
in the absence of QH1 staining (green) denotes cells we
operationally define as angioblasts (arrowheads, Fig. 6b). In
contrast, the descendents of angioblasts, primordial endo-
thelial cells, appear as yellow/green/red clusters. In most
cases angioblasts (QH12/Tal11) are not in clusters, but are
resent as isolated cells. The data in Fig. 6 indicate that
s of reproduction in any form reserved.
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184 Drake et al.induction of vascular precursor cells from the splanchnic
mesoderm was not halted by VEGF inhibitors.
Analysis of soluble VEGFR-1-treated embryos double
immunolabeled with QH1 and TAL1 also revealed abnor-
malities in both the organization and the patterning of
vessels (Fig. 6). Specifically, QH1 immunofluorescence re-
vealed poorly spread clusters of endothelial cells (green/
yellow fluorescence, Fig. 6b). Indeed, the general phenotype
was virtually identical to cellular clusters in embryos
injected at four to nine somites (Figs. 1, 2, 3, and 5).
DISCUSSION
How diversity in vessel size and vascular patterning is
generated in the absence of blood flow remains an enigma.
One plausible explanation is that local morphogenic cues
direct early vascular morphogenesis. Notable among the
FIG. 5. Double immunofluorescence shows that VEGF/VEGF re
extension. The images show that de novo morphogenesis of endoth
ignaling is the formation of an extended, bipolar shape. (a and
EGFR-1-treated embryo. Both specimens were double immuno
rogenitor cells. Comparing the two images it is evident, as judge
ells are required to complete a polygonal segment. Indeed, as few
umerous TAL1-positive cells are present in the soluble VEGFR-1
orphology required to form a primary vascular pattern. The
AL1-positive cells in injected embryos are distributed in comp
xtended shape characteristic of primordial endothelial cells. Thes
esponsible for the failure of vasculogenesis in soluble VEGFR-1-inmany candidate molecules is VEGF. A role for VEGF in s
Copyright © 2000 by Academic Press. All rightnfluencing vasculogenesis is supported by a number of in
ivo studies addressing the consequences of disrupting
ormal VEGF/VEGF receptor signaling (Carmeliet et al.,
996; Ferrara et al., 1996; Fong et al., 1995; Shalaby et al.,
995). This body of work establishes the importance of
orrect VEGF/VEGF receptor signaling to early vascular
orphogenesis.
Vasculogenesis and VEGF/VEGFR-Modulated
Protrusive Activity
Although the above studies demonstrate the importance
of VEGF/VEGF receptor signaling, the cellular behavior
underlying VEGF activity(ies) remains obscure. We propose
that one such activity is the regulation of angioblast/
endothelial cell protrusive activity. Both our in vivo gain-
f-function and loss-of-function experiments are consistent
ith VEGF playing such a role. The data show that exces-
or signaling regulates primordial endothelial cell protrusion and
tubes requires VEGF signaling and that an early response to normal
he vascular networks of a control embryo. (c and d) A soluble
led with QH1 and TAL1; the latter marker identifies vascular
the TAL1-immunopositive nuclei, that relatively few endothelial
o cells are able to form one side of a polygon (arrows). Although
cted embryo (c and d) there is a complete absence of the cellular
striking difference is the shape of the endothelial cells. The
quasi-rounded clusters; in contrast, control embryos display the
ta also show that a diminished population of vascular cells is not
d embryos. Original magnification 2603. Bar, 15 mm.cept
elial
b) T
labe
d by
as tw
-inje
most
act,
e daive levels of VEGF lead to an increase in endothelial cell
s of reproduction in any form reserved.
at approximately 7 somites. QH1, in green, depicts endothelial cell
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Copyright © 2000 by Academic Press. All rightprotrusive activity (Fig. 4), while the introduction of soluble
VEGF receptor inhibited protrusive activity (Figs. 1–3, 5,
and 6). The inhibitory effect of soluble receptor is presumed
to be the result of the recombinant receptor binding endog-
enous ligand(s), thus competitively inhibiting normal
VEGF-mediated signaling. Inhibitory effects were evident
by both poorly extended angioblast/endothelial cells and a
failure in the formation of vascular polygons.
If protrusive activity is a critical element of vasculogen-
esis, it follows that endothelial cells must engage in extra-
cellular matrix adhesions to form such processes. Our
previous work in avians demonstrated that integrin-based
angioblast/endothelial cell adhesion is required for the
genesis of blood vessels and vascular networks. The data
showed that both b1 and avb3 integrins are involved in
vasculogenesis (Drake et al., 1992, 1995). The failure of
treated embryos to organize vascular networks was attrib-
uted to the inability of angioblast/endothelial cells to
engage extracellular integrin ligands. This loss of integrin-
mediated activity manifested itself as a striking inhibition
of normal shape-change and protrusive behavior(s). The
possibility that integrin–extracellular matrix adhesions are
required for vascular morphogenesis is supported by work
examining the role of avb3 receptor during angiogenesis
(Brooks et al., 1994; Friedlander et al., 1995).
The most compelling data linking VEGF activity to
downstream cell–extracellular matrix adhesive activity is
the work of Senger and colleagues (1996). In studies using
cultured microvascular endothelial cells these investigators
demonstrated that introduction of exogenous VEGF
strongly up-regulated integrin expression, suggesting that,
at least in this case, integrin expression is downstream of
VEGF stimulation. While not conclusive with respect to
the avian embryo, these data are compatible with our
surfaces, while the red fluorescence denotes cells expressing the
transcription factor TAL1, a marker of vascular progenitor cells or
angioblasts (see Drake and Little, 1997; Drake and Flemming,
2000). (a) The soluble VEGFR-1-induced vascular anomalies were
virtually the same as those observed in embryos injected at later
somitic stages (Figs. 1 and 2). Of more interest is the observation
that despite injection of the VEGF inhibitor at these very early
stages, endothelial precursor cells continued to emerge. (b) A higher
magnification of the area denoted by the box in a. This image
shows the superimposition of both red and green florescence image
channels. Endothelial cells are contained in clusters exhibiting red,
yellow, and green immunofluorescence. The yellow depicts areas
where the two staining patterns overlap. Other cells are conspicu-
ous by the absence of yellow and green fluorescence and the sole
presence of red immunofluorescence (arrowheads). Such cells are
considered to be vascular precursor cells or angioblasts. Notably,
the inhibition of VEGF signaling in 1- to 2-somite embryos did not
prevent the appearance of precursors during the 7-h incubation
(arrowheads). These data strongly suggest that angioblast induc-FIG. 6. VEGF does not appear to be required for the induction of
vascular precursor cells. Embryos injected with soluble VEGFR-1 at
the 1- or 2-somite stage were analyzed using double immunofluo-
rescence after 7 h of incubation, at which time the specimens weretion, from primary mesoderm, is not initiated by VEGF signaling.
s of reproduction in any form reserved.
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186 Drake et al.current and previous observations regarding vasculogenesis
and cell protrusive activity. Thus, data from a number of
sources establish a correlation between VEGF/VEGF recep-
tor signaling, integrin expression, and angioblast/
endothelial cell protrusive activity. We are aware that many
other cellular activities could be downstream of VEGF
signaling and might therefore influence our observations
(i.e., endothelial cell interactions).
VEGF/VEGF Receptor-Modulated Protrusive
Activity and the Assembly of Primary Vascular
Networks and Large Vessels
This study and our previous work indicate that VEGF/
VEGF receptor-modulated protrusive activity is critical for
the assembly of primary vascular networks. In this regard
VEGF/VEGF receptor signaling acts to direct the
protrusive/extension behavior(s) of angioblasts and endo-
thelial cells within the splanchnopleural ECM. Based on
our recent analysis of blood vessels and vascular network
formation in the quail embryo, protrusions appear to be
required for isolated angioblasts to form the interconnected
polygonal vascular arrangements that we refer to as primary
vascular networks (Drake et al., 1997).
Our findings also indicate that VEGF/VEGF receptor-
modulated protrusive activity is required during the mor-
phogenesis of larger vessels and vascular sinuses; moreover,
the process appears to be similar to that observed in the
formation of primary vascular networks. The idea that
VEGF/VEGF receptor signaling could account for the for-
mation of large vessels arose as part of earlier studies
examining the effects of elevated levels of VEGF on vascu-
lar morphogenesis (Drake and Little, 1995). In these studies
normal vascular development was subverted and replaced
by enlarged vascular sinuses. We refer to this activity as
vascular hyperfusion. More recently we proposed that vas-
cular fusion is a normal morphogenetic process required for
the formation of large vessels during vasculogenesis (Drake
et al., 1998; Drake and Little, 1998, 1999). We propose that
vascular fusion behavior is mediated by VEGF/VEGF recep-
tor signaling, the morphogenic endpoint being the coales-
cence of small-caliber vessels into larger vessels. Observa-
tions of vascular beds where fusion takes place (the
primordia of the dorsal aortae and sinus venous) indicate
that the process occurs in the following sequence—In
response to VEGF/VEGF receptor signaling, cells within a
vascular polygon engage in extension/protrusion behavior
leading to contact between endothelial cells (tubes) on
opposite sides of a vascular polygon. This results in forma-
tion of a new endothelial tube which extends across the
“diameter” of the polygon. This, by necessity, involves
vascular fusion, a process whereby two vessels connect and
from a common lumen. When repeated this protrusion-
linked iterative process consolidates vascular polygons and
thereby reduces the avascular area. Normal vascular fusion,
we propose, results in the establishment of major vessels
such as the dorsal aortae, endocardium, and sinus venosae. e
Copyright © 2000 by Academic Press. All rightor a diagrammatic representation of this process see Drake
nd Little (1999).
The notion that endothelial cells can engage in vascular
usion is not a novel concept. For example, such a phenom-
non operates when bilateral primordia, such as the dorsal
ortae and endocardia, fuse to form midline structures.
hat is novel in our model is that this activity is: (1)
roposed to operate during formation of the small-caliber
lood vessels that constitute primary vascular networks
nd (2) regulated by VEGF/VEGF receptor signaling.
Data presented above strongly support our concept of
ascular fusion. When embryos received a high dose of
oluble receptor the development of the sinus venosus was
rrested. In the region which normally gives rise to the
inus, small vascular polygons were observed (arrowhead,
ig. 2a). Thus, experimental neutralization of endogenous
EGF results in the failure to form a normal sinus venosus
y inhibiting normal vascular fusion (Fig. 2a). In contrast,
reatment with exogenous VEGF165 leads to formation of
reatly oversized vascular sinuses at positions where no
uch structures form in normal embryos (Fig. 4; also see
rake and Little, 1995). Experimental manipulation of
EGF-mediated signaling varies the degree of vascular
usion. Further, such stimulation or inhibition is always
ccompanied by either excessive or insufficient endothelial
ell protrusive activity (compare Figs. 2a and 4). We con-
lude, therefore, that cell protrusive activity is required for
uccessful vascular fusion.
If our hypothesis—that VEGF regulates vascular
usion—is correct, this concept provides a cellular mecha-
ism for understanding why tumor vessels, and other
athological vasculature, are commonly described as hav-
ng a “dilated” or sinus-like morphology (Bugajski et al.,
989; Konerding et al., 1999). This interpretation stands in
ontrast to the notion that such morphology arises by
dilatation” of smaller vessels.
VEGF Signaling and the Endothelial Cell Lineage
While not directly related to the subject of VEGF/VEGF
receptor-modulated protrusive activity, our interest in vas-
culogenesis led us to explore whether perturbing VEGF/
VEGF receptor signaling influenced the genesis of the
endothelial lineage. Figure 6 shows that injection of soluble
VEGFR-1 at stages before vessel morphogenesis is initiated
(one- to two-somite stage; see Table 1) did not arrest the
formation of the endothelial cells. This is demonstrated by
the presence of angioblasts (TAL1-positive/QH1-negative
cells) after 7 h of incubation. These observations are in
agreement with loss-of-function studies in mice suggesting
that VEGF is not required for initial formation of the
endothelial lineage (Carmeliet et al., 1996; Ferrara et al.,
996).
Based on the fact that quail endothelial cells fail to
rotrude and extend when deprived of VEGF, we propose a
imilar mechanism for the early death of VEGF null mouse
mbryos. Without protrusive activity early mouse embryos
s of reproduction in any form reserved.
B187VEGF Regulates Cell Behaviorcould not form a primary vascular network, leading to
death.
In conclusion, our data provide insight into how normal
vascular morphogenesis is accomplished. VEGF regulates
protrusive/extension activity, a cell behavior required for
vascular pattern formation. Furthermore we demonstrate
that the transition from small-caliber vessels to larger
caliber vessels is governed, in part, by VEGF-based signals.
We contend that these activities represent a normal VEGF/
VEGF receptor function, in vivo. Given its many known
functions the VEGF signaling pathway is likely to be a
high-order control mechanism for multiple endothelial cell
activities. We propose that one of the early VEGF-regulated
control points is modulation of endothelial cell protrusive
activity and formation of an extended cell shape.
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